

Supplementary Materials: Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism *In Vivo*

Brian C. Jensen ^{1,*}, Traci L. Parry, Wei Huang, Amro Ilaiwy, James R. Bain, Michael J. Muehlbauer, Sara K. O'Neal, Cam Patterson, Gary L. Johnson, Monte S. Willis




Figure S1. Heat map of all cardiac metabolites identified by GC-MS in sunitinib-treated animals.




Figure S2. Heat map of all cardiac metabolites identified by GC-MS in erlotinib-treated animals.




Figure S3. Heat map of all liver metabolites identified by GC-MS in sunitinib-treated animals.




Figure S4. Heat map of all liver metabolites identified by GC-MS in erlotinib-treated animals.




Figure S5. Heat map of all quadriceps femoris metabolites identified by GC-MS in sunitinib-treated animals.




Figure S6. Heat map of all quadriceps femoris metabolites identified by GC-MS in erlotinib-treated animals.

